BLAINTRAVENOUSVIALPriority Review
Approved
Oct 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 5h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PROSTASCINT (capromab pendetide) is a radiolabeled monoclonal antibody targeting prostate-specific membrane antigen (PSMA) for imaging and detection of prostate cancer. It is administered intravenously as a diagnostic agent to identify sites of metastatic or recurrent prostate cancer. The drug enables visualization of cancer lesions that may not be detected by conventional imaging modalities.
LOE Approaching
With lifecycle approaching loss of exclusivity and minimal linked job activity, this product faces significant commercial contraction and likely reduced team investment.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Comparison of PET With [89Zr]-Df-IAb2M and [111In]-Capromab Pendetide in the Detection of Prostate Cancer Pre-Prostatectomy
Started Jan 2015
19 enrolled
Prostate Cancer
Career Relevance
PROSTASCINT represents a late-lifecycle diagnostic product with minimal linked career opportunities and declining commercial momentum. Roles in this space typically focus on maintaining existing market share and managing transition to post-exclusivity positioning rather than growth or innovation.
Regional Sales Manager
Worked on PROSTASCINT at Biocytogen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.